Cardioprotective role of insulin: Advantage analogues
Journal of Research in Medical Sciences, 07/17/2012
Clinical Article
Maiti R et al. - Short acting insulin analogues, especially aspart insulin have been found to have a better cardio protective role than regular human insulin (RHI) in Type II diabetes mellitus (DM).
Methods- A randomized, open, parallel group, comparative clinical study was conducted on 90 patients of type II DM.
- After baseline clinical assessment and investigations, RHI was prescribed to 30 patients, aspart insulin to 30 patients and lispro insulin to another 30 patients for 12 weeks.
- The efficacy variables were change in blood pressure, glycemic control, lipid profile, serum potassium, high-sensitivity CRP (hsCRP) and UKPDS 10-year CHD risk scoring over 12 weeks.
- At the end of the study, the patients were followed up and changes in variables from baseline were analyzed by statistical tools.
- Systolic blood pressure decreased significantly in aspart group (P = 0.008) whereas diastolic blood pressure was decreased significantly both in aspart (P < 0.001) and lispro group (P = 0.01).
- Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).
- Triglyceride was significantly better controlled by lispro (P < 0.01) whereas aspart insulin was superior to decrease total cholesterol and LDL (P < 0.05).
- The extent of potassium loss was significantly more with RHI (P = 0.004) than others.
- CRP-lowering effect (P = 0.017) and decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to RHI group.
